A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
← catalyst calendarSponsored by Atara Biotherapeutics (industry) · ATRA — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
1actual
Sites
6
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Financial reasons
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-06 | actual | When the study began enrolling |
| Primary completion | 2025-03-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-30 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Intervention
- Drug: ATA3219
Primary outcomes
what the primary-completion date above is the date OFIncidence and Severity of Treatment-emergent Adverse Events (TEAEs)
measured Day 1 through 90 days after the last dose of study drug
Incidence and Severity of Adverse Events of Special Interest (AESIs)
measured Day 1 through 90 days after the last dose of study drug
Number of Participants With Clinically Significant Changes in Laboratory Parameters
measured Day 1 through 90 days after the last dose of study drug
Incidence of Dose-limiting Toxicities (DLTs)
measured Day 1 through Day 28 of first dose
Maximum Tolerated dose (MTD)
measured Day 1 through Day 28 of first dose
Recommended Phase 2 Dose (RP2D)
measured Day 1 through Day 28 of first dose
Publications
- PMID 35732829 — reports results
- PMID 25113753 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ATRA's whole pipeline · Catalyst calendar · Every registered study · What changed